Reprogrammed Interchange Llc Sells 7,901 Shares of Vor Biopharma (NYSE:VOR) Stock

Vor Biopharma Inc. (NYSE:VOR) major shareholder Reprogrammed Interchange Llc sold 7,901 shares of the company’s stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $37.83, for a total transaction of $298,894.83. Following the completion of the sale, the insider directly owned 1,597,308 shares of the company’s stock, valued at $60,426,161.64. The trade was a 0.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Thursday, October 2nd, Reprogrammed Interchange Llc sold 32,451 shares of Vor Biopharma stock. The shares were sold at an average price of $39.83, for a total transaction of $1,292,523.33.
• On Wednesday, October 1st, Reprogrammed Interchange Llc sold 1,400 shares of Vor Biopharma stock. The stock was sold at an average price of $39.19, for a total value of $54,866.00.
• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 447,278 shares of Vor Biopharma stock. The shares were sold at an average price of $1.54, for a total value of $688,808.12.
• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 22,363 shares of Vor Biopharma stock. The stock was sold at an average price of $30.80, for a total value of $688,780.40.
• On Monday, September 15th, Reprogrammed Interchange Llc sold 20,000 shares of Vor Biopharma stock. The stock was sold at an average price of $32.80, for a total value of $656,000.00.
• On Friday, September 12th, Reprogrammed Interchange Llc sold 15,000 shares of Vor Biopharma stock. The shares were sold at an average price of $35.00, for a total value of $525,000.00.
• On Thursday, September 11th, Reprogrammed Interchange Llc sold 14,240 shares of Vor Biopharma stock. The shares were sold at an average price of $36.60, for a total value of $521,184.00.
• On Monday, September 8th, Reprogrammed Interchange Llc sold 23,221 shares of Vor Biopharma stock. The stock was sold at an average price of $39.80, for a total transaction of $924,195.80.
• On Wednesday, September 10th, Reprogrammed Interchange Llc sold 17,500 shares of Vor Biopharma stock. The shares were sold at an average price of $36.40, for a total transaction of $637,000.00.
• On Tuesday, September 9th, Reprogrammed Interchange Llc sold 22,461 shares of Vor Biopharma stock. The stock was sold at an average price of $40.00, for a total transaction of $898,440.00.

Vor Biopharma Stock Up 2.1%

NYSE VOR opened at $37.46 on Monday. Vor Biopharma Inc. has a 52 week low of $2.62 and a 52 week high of $65.80. The company has a 50 day moving average price of $38.88 and a 200 day moving average price of $24.25. The firm has a market cap of $256.75 million, a PE ratio of -22.70 and a beta of 2.07.

Institutional Trading of Vor Biopharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. XTX Topco Ltd purchased a new stake in Vor Biopharma during the 2nd quarter valued at about $66,000. Goldman Sachs Group Inc. lifted its holdings in shares of Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after purchasing an additional 58,247 shares during the period. Jane Street Group LLC purchased a new stake in Vor Biopharma in the first quarter valued at approximately $140,000. OMERS ADMINISTRATION Corp acquired a new position in Vor Biopharma in the 1st quarter worth approximately $100,000. Finally, Money Concepts Capital Corp raised its position in Vor Biopharma by 106.1% during the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company’s stock worth $37,000 after buying an additional 26,535 shares during the last quarter. Institutional investors and hedge funds own 97.29% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Wedbush reiterated an “outperform” rating on shares of Vor Biopharma in a report on Thursday, June 26th. Stifel Nicolaus upgraded Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 price target for the company in a research note on Wednesday, September 24th. Finally, HC Wainwright restated a “buy” rating and set a $60.00 price target on shares of Vor Biopharma in a research note on Thursday, August 14th. Five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $113.83.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.